Oric Pharmaceuticals (NASDAQ:ORIC) CEO Sells $414,801.38 in Stock

Key Points

• Jacob Chacko, CEO of Oric Pharmaceuticals, sold a total of $414,801.38 in stock by unloading 34,538 shares, representing a 5.26% decrease in his ownership position.
• Oric Pharmaceuticals recently reported a quarterly earnings loss of ($0.47) per share, which was below analysts' expectations of ($0.46).
• Institutional investors hold 95.05% of Oric Pharmaceuticals' stock, with significant recent increases in positions from firms like Nisa Investment Advisors and Tower Research Capital.

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CEO Jacob Chacko sold 34,538 shares of the stock in a transaction dated Tuesday, September 30th. The stock was sold at an average price of $12.01, for a total value of $414,801.38. Following the transaction, the chief executive officer owned 621,881 shares of the company's stock, valued at approximately $7,468,790.81. This trade represents a 5.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Jacob Chacko also recently made the following trade(s):

• On Wednesday, October 1st, Jacob Chacko sold 53,001 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $12.05, for a total transaction of $638,662.05.
• On Monday, September 22nd, Jacob Chacko sold 125,000 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.80, for a total transaction of $1,350,000.00.

Oric Pharmaceuticals Trading Down 3.3%

Shares of Oric Pharmaceuticals stock traded down $0.39 during trading hours on Thursday, reaching $11.32. 1,297,755 shares of the company's stock were exchanged, compared to its average volume of 1,392,198. The company has a 50 day moving average of $10.39 and a two-hundred day moving average of $8.49. Oric Pharmaceuticals, Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.67. The stock has a market cap of $1.10 billion, a P/E ratio of -5.99 and a beta of 1.68.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01). As a group, analysts expect that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ORIC shares. JPMorgan Chase & Co. cut their target price on shares of Oric Pharmaceuticals from $20.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, August 14th. LADENBURG THALM/SH SH started coverage on shares of Oric Pharmaceuticals in a report on Tuesday, July 8th. They set a "buy" rating and a $15.00 target price on the stock. Guggenheim started coverage on shares of Oric Pharmaceuticals in a report on Thursday, September 4th. They set a "buy" rating and a $18.00 target price on the stock. Wedbush reaffirmed an "outperform" rating and set a $20.00 target price on shares of Oric Pharmaceuticals in a report on Monday, June 23rd. Finally, HC Wainwright decreased their price objective on shares of Oric Pharmaceuticals from $22.00 to $19.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.29.

Institutional Investors Weigh In On Oric Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC increased its position in shares of Oric Pharmaceuticals by 17,300.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company's stock worth $25,000 after acquiring an additional 2,422 shares in the last quarter. ANTIPODES PARTNERS Ltd boosted its stake in Oric Pharmaceuticals by 35.9% in the second quarter. ANTIPODES PARTNERS Ltd now owns 5,194 shares of the company's stock valued at $53,000 after acquiring an additional 1,372 shares during the last quarter. Arizona State Retirement System purchased a new position in Oric Pharmaceuticals in the first quarter valued at about $56,000. Creative Planning purchased a new stake in shares of Oric Pharmaceuticals during the 2nd quarter valued at approximately $113,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Oric Pharmaceuticals by 1,293.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,757 shares of the company's stock valued at $119,000 after buying an additional 10,913 shares in the last quarter. 95.05% of the stock is owned by institutional investors.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.